Home  |  Contact

Cellosaurus PA-1 (CVCL_0479)

[Text version]

Cell line name PA-1
Synonyms PA1; PA I; PAI
Accession CVCL_0479
Resource Identification Initiative To cite this cell line use: PA-1 (RRID:CVCL_0479)
Comments Part of: Cancer Cell Line Encyclopedia (CCLE) project.
Part of: COSMIC cell lines project.
Part of: KuDOS 95 cell line panel.
Doubling time: 36 hours (PubMed=2653399); 22.77 hours (https://www.synapse.org/#!Synapse:syn2347014).
Microsatellite instability: Stable (MSS) (Sanger).
Omics: Deep exome analysis.
Omics: Deep RNAseq analysis.
Omics: DNA methylation analysis.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Caution: TP53 mutation indicated to be at p.Asn239Asp (c.715A>G) in DOI=10.11418/jtca1981.16.3_173 and PubMed=9359923.
Discontinued: TKG; TKG 0573; true.
Sequence variations Heterozygous for NRAS p.Gly12Asp (c.35G>A) (ClinVar=VCV000039648); not found in early passages (PubMed=6740333).
Heterozygous for TP53 p.Pro316Pro (c.948C>T) (Cosmic-CLP).
Genome ancestry Source: PubMed=30894373

Origin% genome
African21.08
Native American17.69
East Asian, North1.54
East Asian, South0.7
South Asian0.4
European, North26.01
European, South32.58
Disease Ovarian mixed germ cell tumor (NCIt: C8114)
Mixed germ cell tumor (ORDO: Orphanet_180234)
Derived from metastatic site: Ascites.
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children:
CVCL_1T15 (222)CVCL_4992 (CH1 [Human ovarian carcinoma])CVCL_3121 (PA-1/6TG-r)
Sex of cell Female
Age at sampling 12Y
Category Cancer cell line
STR profile Source(s): ATCC; CCRID; CLS; COG; Cosmic-CLP; ECACC; JCRB; PubMed=25877200

Markers:
AmelogeninX
CSF1PO9,12
D2S133824
D3S135815
D5S81811
D7S8209
D8S117914,15
D13S3179,10 (ATCC; CCRID; CLS; COG; Cosmic-CLP; ECACC; PubMed=25877200)
9,10,13 (JCRB)
D16S5399,12 (ATCC; CCRID; COG; Cosmic-CLP; ECACC; JCRB; PubMed=25877200)
9 (CLS)
D18S5115,18
D19S43313
D21S1129,31.2
FGA24
Penta D9,12
Penta E14,20
TH017,9
TPOX11
vWA15,17

Run an STR similarity search on this cell line
Web pages http://www.cellresource.cn/fdetail.aspx?id=21
Publications

PubMed=6931103; DOI=10.1002/ijc.2910250104
Zeuthen J., Norgaard J.O.R., Avner P., Fellous M., Wartiovaara J., Vaheri A., Rosen A., Giovanella B.C.
Characterization of a human ovarian teratocarcinoma-derived cell line.
Int. J. Cancer 25:19-32(1980)

PubMed=6740333; DOI=10.1126/science.6740333
Tainsky M.A., Cooper C.S., Giovanella B.C., Vande Woude G.F.
An activated rasN gene: detected in late but not early passage human PA1 teratocarcinoma cells.
Science 225:643-645(1984)

PubMed=2653399; DOI=10.1038/bjc.1989.108
Hills C.A., Kelland L.R., Abel G., Siracky J., Wilson A.P., Harrap K.R.
Biological properties of ten human ovarian carcinoma cell lines: calibration in vitro against four platinum complexes.
Br. J. Cancer 59:527-534(1989)

DOI=10.11418/jtca1981.16.3_173
Mihara K., Miyazaki M., Fushimi K., Tsuji T., Inoue Y., Fukaya K.-I., Ohashi R., Namba M.
The p53 gene status and other cellular characteristics of human cell lines maintained in our laboratory.
Tissue Cult. Res. Commun. 16:173-178(1997)

PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D
Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T., Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M., Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.
Screening the p53 status of human cell lines using a yeast functional assay.
Mol. Carcinog. 19:243-253(1997)

PubMed=9359923; DOI=10.18926/AMO/30789
Mihara K., Miyazaki M., Kondo T., Fushimi K., Tsuji T., Inoue Y., Fukaya K.-I., Ishioka C., Namba M.
Yeast functional assay of the p53 gene status in human cell lines maintained in our laboratory.
Acta Med. Okayama 51:261-265(1997)

PubMed=9698466; DOI=10.1006/gyno.1998.5039
Maxwell G.L., Risinger J.I., Tong B., Shaw H., Barrett J.C., Berchuck A., Futreal P.A.
Mutation of the PTEN tumor suppressor gene is not a feature of ovarian cancers.
Gynecol. Oncol. 70:13-16(1998)

PubMed=10567668; DOI=10.3892/ijmm.4.6.597
Gao C., Miyazaki M., Li J.W., Tsuji T., Inoue Y., Namba M.
Cytogenetic characteristics and p53 gene status of human teratocarcinoma PA-1 cells in 407-445 passages.
Int. J. Mol. Med. 4:597-600(1999)

PubMed=11314036; DOI=10.1038/sj.onc.1204211
Forgacs E., Wren J.D., Kamibayashi C., Kondo M., Xu X.L., Markowitz S.D., Tomlinson G.E., Muller C.Y., Gazdar A.F., Garner H.R., Minna J.D.
Searching for microsatellite mutations in coding regions in lung, breast, ovarian and colorectal cancers.
Oncogene 20:1005-1009(2001)

PubMed=11330945; DOI=10.1006/gyno.2001.6132
Watanabe T., Imoto I., Kosugi Y., Ishiwata I., Inoue S., Takayama M., Sato A., Inazawa J.
A novel amplification at 17q21-23 in ovarian cancer cell lines detected by comparative genomic hybridization.
Gynecol. Oncol. 81:172-177(2001)

PubMed=15677628; DOI=10.1093/carcin/bgi032
Gorringe K.L., Chin S.-F., Pharoah P., Staines J.M., Oliveira C., Edwards P.A.W., Caldas C.
Evidence that both genetic instability and selection contribute to the accumulation of chromosome alterations in cancer.
Carcinogenesis 26:923-930(2005)

PubMed=16080959; DOI=10.1016/j.cancergencyto.2005.01.003
Sarraf S., Tejada R., Abawi M., Oberst M., Dennis T., Simon K.C., Blancato J.
The human ovarian teratocarcinoma cell line PA-1 demonstrates a single translocation: analysis with fluorescence in situ hybridization, spectral karyotyping, and bacterial artificial chromosome microarray.
Cancer Genet. Cytogenet. 161:63-69(2005)

PubMed=20164919; DOI=10.1038/nature08768
Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)

PubMed=22710073; DOI=10.1016/j.ygyno.2012.06.017
Korch C., Spillman M.A., Jackson T.A., Jacobsen B.M., Murphy S.K., Lessey B.A., Jordan V.C., Bradford A.P.
DNA profiling analysis of endometrial and ovarian cell lines reveals misidentification, redundancy and contamination.
Gynecol. Oncol. 127:241-248(2012)

PubMed=23415752; DOI=10.1016/j.molonc.2012.12.007
Stordal B., Timms K., Farrelly A., Gallagher D., Busschots S., Renaud M., Thery J., Williams D., Potter J., Tran T., Korpanty G., Cremona M., Carey M.S., Li J., Li Y., Aslan O., O'Leary J.J., Mills G.B., Hennessy B.T.
BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation.
Mol. Oncol. 7:567-579(2013)

PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z., Liu H., Degenhardt J., Mayba O., Gnad F., Liu J., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

Cross-references
Cell line collections ATCC; CRL-1572
BCRC; 60063
CLS; 300402/p655_PA-1
ECACC; 90013101
ICLC; HTL97002
IZSLER; BS TCL 179
JCRB; JCRB9061
RCB; RCB1946 - Discontinued
TKG; TKG 0573
Cell line databases/resources CLDB; cl3856
CLDB; cl3857
CLDB; cl3858
CLDB; cl3859
CCLE; PA1_OVARY
CCRID; 3111C0001CCC000021
Cell_Model_Passport; SIDM01140
CGH-DB; 9358-4
Cosmic-CLP; 909255
DepMap; ACH-001374
LINCS_LDP; LCL-1416
Ontologies BTO; BTO:0001591
CLO; CLO_0008350
EFO; EFO_0006465
MCCL; MCC:0000377
Biological sample resources BioSample; SAMN01821586
BioSample; SAMN03473209
BioSample; SAMN03472415
Chemistry resources ChEMBL-Cells; CHEMBL3308812
ChEMBL-Targets; CHEMBL614949
GDSC; 909255
PharmacoDB; PA1_1235_2019
Gene expression databases ArrayExpress; E-MTAB-783
ArrayExpress; E-MTAB-2706
ArrayExpress; E-MTAB-3610
GEO; GSM186444
GEO; GSM186445
GEO; GSM784566
GEO; GSM1374804
GEO; GSM1670330
Other Wikidata; Q54937331
Polymorphism and mutation databases Cosmic; 688112
Cosmic; 801353
Cosmic; 809111
Cosmic; 844343
Cosmic; 909255
Cosmic; 931368
Cosmic; 1305331
Cosmic; 1995610
IARC_TP53; 1418
IARC_TP53; 8338
Entry history
Entry creation04-Apr-2012
Last entry updated02-Jul-2020
Version number33